MAP3K20

Across TCGA pan-cancer cohorts, MAP3K20 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAP3K20 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher MAP3K20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAP3K20 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

READ, LUAD, and UCEC are the cancer types where MAP3K20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	II,III,IV	0.111	0.919	<.001	41	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	35	view →
UCEC	DFS	Median	All	0.966	0.825	.010	24	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
HNSC	OS	Median	IV	0.013	0.733	<.001	12	view →
SARC	DFS	Median	All	0.109	0.611	.030	6	view →
SKCM	OS	Median	All	0.124	0.325	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAP3K20–READ (OS)

Open the READ breakdown →